IDXX IDEXX Laboratories, Inc.
IDXX IDEXX Laboratories, Inc.
Healthcare · Diagnostics & Research
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $562.34 · VWAP $601.96 · -6.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
IDXX Price Structure
Loading timeframes…
Peers
Every watchlist IDXX belongs to, members best 30-day change first — IDXX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@livestock-disease
Reported the quarter ending 2026-06-30: revenue $1.22B, diluted EPS $4.27, net income $338M (SEC filing). Across the print the stock moved +3.0% (close before → first close after).
full note →Against street estimates
How IDXX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
IDXX research tape
7 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.